Pfizer Inc said on Tuesday it will start a large study to test its COVID-19 vaccine in children below 12 and selected a dosing regime for the trial.
The study will enroll up to 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain, the company said.
Get weekly health news
READ MORE: What we know about the heart reaction reported after COVID-19 vaccines
Pfizer’s vaccine has been authorized for use in children as young as 12 in Europe, the United States and Canada.
- Canadian teacher in Venezuela describes chaos as earthquakes’ death toll climbs
- Burnaby Urban Search and Rescue team deploys to Venezuela after deadly earthquakes
- An ‘Omega block’ is behind Europe’s heat wave — can it happen in Canada?
- Israel, Lebanon sign framework deal with U.S. seen as ‘first step’ to peace
-
![]()
This Week in Washington: U.S. response to Venezuela earthquake, fragile talks between Trump and Iran -
![]()
Future of 24 Sussex Drive up for redesign under Carney plan -
![]()
Death toll climbs in Venezuela after two devastating quakes, Red Cross races to help -
![]()
Burnaby Urban Search and Rescue team deploys to Venezuela after deadly earthquakes
The company said it has selected a dose of 10 micrograms in children between five and 11 years of age and three micrograms for infants in age-group of six months to five years -old.
Inoculating children and young people is considered a critical step toward reaching “herd immunity” and taming the COVID-19 pandemic.
Comments
Want to discuss? Please read our Commenting Policy first.